151 related articles for article (PubMed ID: 2992990)
1. Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
Lundh H; Nilsson O; Rosén I
Eur Arch Psychiatry Neurol Sci; 1985; 234(6):374-7. PubMed ID: 2992990
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
Lundh H; Nilsson O; Rosén I
Neurology; 1984 Oct; 34(10):1324-30. PubMed ID: 6541305
[TBL] [Abstract][Full Text] [Related]
3. Novel drug of choice in Eaton-Lambert syndrome.
Lundh H; Nilsson O; Rosén I
J Neurol Neurosurg Psychiatry; 1983 Jul; 46(7):684-5. PubMed ID: 6310051
[No Abstract] [Full Text] [Related]
4. Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
Riggs JE
Clin Neuropharmacol; 1982; 5(3):277-92. PubMed ID: 6288236
[No Abstract] [Full Text] [Related]
5. Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.
Morsch M; Reddel SW; Ghazanfari N; Toyka KV; Phillips WD
J Physiol; 2013 May; 591(10):2747-62. PubMed ID: 23440963
[TBL] [Abstract][Full Text] [Related]
6. The effects of 3,4-diaminopyridine on acetylcholine release at the frog neuromuscular junction.
Durant NN; Marshall IG
Eur J Pharmacol; 1980 Oct; 67(2-3):201-8. PubMed ID: 6970132
[TBL] [Abstract][Full Text] [Related]
7. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
[TBL] [Abstract][Full Text] [Related]
8. Ineffectiveness of 3,4-diaminopyridine as a therapy for type C botulism.
Siegel LS; Price JI
Toxicon; 1987; 25(9):1015-8. PubMed ID: 3433299
[TBL] [Abstract][Full Text] [Related]
9. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.
Mann R; Blobner M; Jelen-Esselborn S; Busley R; Werner C
Anesthesiology; 2000 Aug; 93(2):346-50. PubMed ID: 10910480
[TBL] [Abstract][Full Text] [Related]
10. 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis.
Mori S; Kishi M; Kubo S; Akiyoshi T; Yamada S; Miyazaki T; Konishi T; Maruyama N; Shigemoto K
J Neuroimmunol; 2012 Apr; 245(1-2):75-8. PubMed ID: 22409941
[TBL] [Abstract][Full Text] [Related]
11. Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K; Calvey TN
Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):596-601. PubMed ID: 199393
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of experimental autoimmune myasthenia gravis in rabbits with 4-aminopyridine and 3,4-diaminopyridine].
Li L; Zhang YP
Zhongguo Yao Li Xue Bao; 1994 Jul; 15(4):358-62. PubMed ID: 7801782
[TBL] [Abstract][Full Text] [Related]
13. Effect of 3,4-diaminopyridine and tetraethylammonium on the presynaptic blockade caused by beta-bungarotoxin.
Chang CC; Su MJ
Toxicon; 1980; 18(4):481-4. PubMed ID: 6259776
[No Abstract] [Full Text] [Related]
14. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction.
Kauffman JA; Way JF; Siegel LS; Sellin LC
Toxicol Appl Pharmacol; 1985 Jun; 79(2):211-7. PubMed ID: 2988154
[TBL] [Abstract][Full Text] [Related]
15. 4-aminopyridine-a review.
Soni N; Kam P
Anaesth Intensive Care; 1982 May; 10(2):120-6. PubMed ID: 6285756
[TBL] [Abstract][Full Text] [Related]
16. Effects on neuromuscular function of acute chronic exposure to cholinesterase inhibitors in man and in the rat.
Roberts DV; Taylor K; Wilson A
J Physiol; 1971 Dec; 219(2):15P. PubMed ID: 4333825
[No Abstract] [Full Text] [Related]
17. A comparison of 3,4-diaminopyridine and 4-aminopyridine in the anaesthetized cat.
Durant NN; Nguyen N; Lee C; Katz RL
Eur J Pharmacol; 1982 Oct; 84(3-4):215-9. PubMed ID: 6293848
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Sanders DB; Massey JM; Sanders LL; Edwards LJ
Neurology; 2000 Feb; 54(3):603-7. PubMed ID: 10680790
[TBL] [Abstract][Full Text] [Related]
19. The effects of pentachlorophenol (PCP) at the toad neuromuscular junction.
Montoya GA; Quevedo L
Comp Biochem Physiol C Comp Pharmacol Toxicol; 1990; 96(1):193-7. PubMed ID: 1980876
[TBL] [Abstract][Full Text] [Related]
20. Mivacurium chloride and myasthenia gravis.
Seigne RD; Scott RP
Br J Anaesth; 1994 Apr; 72(4):468-9. PubMed ID: 8155454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
